Cosmos Pharmaceutical Limited | ZOLIDON®
Cosmos Limited is one of the leading manufacturers of pharmaceutical products in Kenya and East Africa. Through our specialized Human Health and Animal Health.
Cosmos Limited,top pharmaceutical,top pharma,best pharma,best pharmaceutical,leading pharma,leading pharmaceutical,pharma,cosmos pharmaceutical,cosmos,cosmos Kenya,top pharmaceutical,best pharmaceutical,leading pharmaceutical,medicine,veterinary,animal health,human health,company,companies,manufacturer in Kenya,manufacturers in Kenya,Delvin Mugo,Mugo Delvin,manufacturers in east Africa,manufacturers in Africa ,Cosmos, cosmos pharmaceuticals,pharmaceuticals, pharmaceutical,pharmaceutical company in Kenya,pharmaceuticals companies in Kenya,pharmaceutical company in Nairobi, pharmaceuticals companies in Nairobi,pharmaceuticals companies Nairobi,Kenya pharmaceuticals companies,Nairobi pharmaceuticals,top pharma,best pharma,leading pharma,pharma,top pharmaceutical,best pharmaceutical,leading pharmaceutical,medicine,veterinary,animal health,human health,Kenya pharmaceutical,best medicine,Kenya best medicine,Nairobi manufacturer,best manufacturer,profitable company in Kenya,company,companies,manufacturer in Kenya,manufacturers in Kenya,manufacturers in east Africa,manufacturers in Africa,pharmacy in Kenya,pharmaceutical supplies in Kenya,pharmacies in Kenya,chemists in Kenya,chemist in Kenya,pharmaceutical companies in Kenya,leading pharmaceutical in Kenya, best pharmaceutical in Nairobi,best pharmaceutical in Kenya, pharmaceuticals companies Nairobi, pharmaceuticals companies Kenya, pharmaceuticals products distributor in Nairobi, pharmaceuticals products distributor in Kenya,Kenya Quality Healthcare Products, Quality Healthcare Products,A renown Pharmaceutical company in Kenya,A renown Pharmaceutical
page-template,page-template-full_width,page-template-full_width-php,page,page-id-17934,ajax_updown_fade,page_not_loaded,,side_area_uncovered_from_content,overlapping_content,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-theme-ver-13.6,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.5,vc_responsive



Cefuroxime is a second-generation cephalosporin antibiotic.
Cefuroxime is bactericidal and has a similar spectrum of antimicrobial action and pattern of resistance to those of cefamandole. It is more resistant to hydrolysis by beta-lactamases than cefamandole, and therefore may be more active against beta-lactamase-producing strains of, for example, Haemophilus influenzae and Neisseria gonorrhoeae.


Cefuroxime Axetil is absorbed from the gastro-intestinal tract and is rapidly hydrolysed in the intestinal mucosa and blood to Cefuroxime; absorption is enhanced in the presence of food. Peak plasma concentrations are reported about 2 to 3 hours after an oral dose. Upto 50% of Cefuroxime in the circulation is bound to plasma proteins. The plasma half-life is about 70 minutes and is prolonged in patients with renal impairment and in neonates. Cefuroxime is widely distributed in the body including pleural fluid, sputum, bone, synovial fluid, and aqueous humour, but only achieves therapeutic concentrations in the CSF when the meninges are inflamed. It crosses the placenta and has been detected in breast milk. Cefuroxime is excreted unchanged, by glomerular filtration and renal tubular secretion, and high concentrations are achieved in the urine. Small amounts of Cefuroxime are excreted in bile.



Cefuroxime is  used in the treatment of susceptible infections. These have included bone and joint infections, bronchitis (and other lower respiratory-tract infections), gonorrhoea, meningitis, otitis media, peritonitis, pharyngitis, sinusitis, skin infections (including soft-tissue infections), and urinary-tract infections. It is also used for the prophylaxis against post surgical infections.


Usual oral doses for adults are 125mg twice daily for uncomplicated urinary-tract infections and 250 to 500mg twice daily for respiratory-tract infections. A dose for children more than 3 months of age is 125mg twice daily or 10mg per kg body-weight twice daily to a maximum of 250mg daily. Children over 2 years of age with otitis media may be given 250mg twice daily or 15mg per kg twice daily to a maximum of 500mg daily. A single 1g oral dose of Cefuroxime has been given for uncomplicated gonorrhoea.
For reconstitution instructions, refer to label / carton.



Cefuroxime should not be given to patients who are hypersensitive to it or to other cephalosporins. Care is also necessary in patients with a history of allergy.
Cefuroxime should be given with caution to patients with renal impairment; dosage reduction may be necessary. Renal and haematological status should be monitored especially during prolonged and high-dose therapy.

Adverse Effects:

Gastro-intestinal disturbances, including diarrhoea, nausea, and vomiting, have occurred in some patients receiving Cefuroxime Axetil. There have been rare reports of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis.


Probenecid reduces the renal clearance of Cefuroxime resulting in higher and more prolonged plasma concentrations of Cefuroxime.


Store in a dry place below 25ºC. Protect from light. Keep all medicines out of the  reach of children.

Prescription Only Medicine (POM)
®Regd. TM                Ref. No.: INS234/08.06

  • ZOLIDON®125 Dry Powder for Suspension

    PresentationOff white granular powder which on reconstitution forms an off white viscous suspension with fruit flavour. Each 5mL spoonful of the resultant suspension contains: Cefuroxime Axetil USP equivalent to Cefuroxime 125mg. Pack size - 50ml

  • ZOLIDON®500 Tablets F/C

    PresentationWhite, capsule shaped, biconvex, film coated tablet embossed '500' on one side and plain on the other side. Each film coated tablet contains: Cefuroxime Axetil USP equivalent to Cefuroxime 500mg. Pack size - 10's (2x5's)